Context
MedinCell is a phase III pharma company developing a portfolio of long-acting injectable products in various therapeutic areas.
Its BEPO® technology is a polymer-based formulation ensuring the controlled release of an API over a targeted period of days, weeks, or months.
Potential to create a global schizophrenia franchise in partnership with TEVA : currently conducting phase III trial for 2-month risperidone, the most advanced drug candidate.
First non-opioid intraarticular pain and inflammation treatment post orthopedic surgery in phase II.
Ongoing R&D programs in contraception with the Bill & Melinda Gates Foundation and in CNS with multiple indications.
The Company’s objective is to file at least one new IND every year.
IPO proceeds will be used to accelerate pipeline expansion and to further invest in the proprietary technology platform.
About MedinCell
MedinCell is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended-release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved adherence, i.e. adherence with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology allows to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple depot of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs approximately 100 people representing over 25 different nationalities.
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner for MedinCell’s €30 million Euronext Paris IPO
Bryan, Garnier & Co acted as Joint Global Coordinator and Joint Bookrunner.
EUR 30 million raised in gross proceeds (EUR 32.5 million including greenshoe).
Strong international demand generated mainly in the US.
Solid book relying on long only healthcare specialist and generalist investors.
TEVA’s EUR 6 million participation to the IPO demonstrates its strong confidence in schizophrenia products being developed, the company’s pipeline and capacity to execute.
MedinCell is entering the very small circle of listed companies on Euronext Paris with a partnered phase III product.
Market capitalization at IPO: EUR 144 million.
This transaction marks Bryan, Garnier & Co’s 17th Healthcare transaction in 2018 and 11th fund-raising for the sector in the public capital markets.
Share